Navigation Links
New Pfizer Oncology Data Across Numerous Cancer Types to be,Presented at ASCO

patients with advanced refractory thyroid cancer.

-- Overall survival in patients with advanced pancreatic cancer treated with axitinib in combination with gemcitabine or gemcitabine alone.

-- Single-agent efficacy and safety of axitinib in advanced, refractory NSCLC.

Signal Transduction

-- A phase II trial evaluated the safety and efficacy of the investigational compound CP-751,871 in combination with paclitaxel and carboplatin as first-line treatment for NSCLC and standard therapy (paclitaxel and carboplatin alone).

Immuno-Oncology

-- Four different presentations evaluating CP-675,206 in metastatic melanoma and one presentation evaluating CP-675,206 in refractory CRC will be unveiled at ASCO.

-- Results from a multi-dose phase I/II clinical trial that evaluated safety, response, and survival in patients with advanced metastatic melanoma treated with CP-675,206 will be presented in an oral presentation. Two different dosing regimens were evaluated in the phase II arm, providing information on the selected dosing regimen in the phase III program.

Pfizer also announced the expansion of the clinical trial program evaluating the efficacy and safety of sunitinib malate in the treatment of breast cancer. Pfizer has initiated three additional phase III trials to further evaluate sunitinib malate in metastatic breast cancer. This robust research program now includes a total of four phase III and two phase II trials and will include more than 2,600 patients worldwide.

Phase III programs evaluating sunitinib malate in CRC, NSCLC and liver cancer will also be initiated. Professionals interested in learning more about sunitinib malate trials in various cancers can access www.suntrials.com - a clinical resource for healthcare providers.

"SUTENT has proven to be an important therapy in the treatment of advanced kidney cancer and imatinib-resistant gastrointestinal stromal tumor, for which it is currently appr
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. New Data Show Pfizers Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
5. MGI Pharma Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
6. MGI Pharma, Inc. Summarizes Data Presented at the 2007 American Society of Clinical Oncology (ASCO) Annual Meeting
7. Hana Biosciences Presents Data On Two Programs At the American Society of Clinical Oncology Annual Meeting
8. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
9. Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
10. CytImmune Presents Positive CYT-6019 Data During the American Society of Clinical Oncology Annual Meeting in Chicago
11. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
(Date:9/23/2014)... Pa. , Sept. 23, 2014 The Pennsylvania ... drugs Sat., Sept. 27, as part of National Prescription ... no questions asked. Take-Back Day is a ... Enforcement Administration (DEA), aimed at encouraging the public to ... are prone to abuse and theft. From ...
(Date:9/23/2014)... , Sept. 23, 2014 Galmed Pharmaceuticals ... clinical-stage biopharmaceutical company focused on the development and ... treatment of liver diseases and cholesterol gallstones, announced ... or the FDA, approved its request for Fast ... the treatment of Non-Alcoholic Steato-Hepatitis, or NASH.  ...
(Date:9/23/2014)... -- Vesselon, Inc. today announced the appointment of Jurgen Raths, ... 2014. Dr. Raths, appointment follows Vesselon,s engagement with Spencer ... a private preferred Series A round to facilitate development ... "Jurgen,s deep experience across multiple functional areas of medical ... as we develop our device that can be compared ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
... 2011 Express Scripts (Nasdaq: ESRX ), one ... announced today its intention to release its third quarter earnings ... will hold its quarterly conference call to discuss third quarter ... Time (8:30 a.m. Central Time). This call is ...
... U.S. Food and Drug Administration has issued a proposed ... classification for external pacemaker pulse generators from Class III ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) External pacemaker pulse generators are ... permanent pacemaker can be implanted. They are also used ...
Cached Medicine Technology:FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 2FDA Proposes Lower Risk Classification, Special Controls for External Pacemakers 3
(Date:9/23/2014)... understanding of how living things function comes from knowledge ... of life, the receptors that are docking stations for ... and RNA that carry genetic blueprints for building cellular ... access to these structural details, a new grant just ... the U.S. Department of Energy (DOE) will fund the ...
(Date:9/23/2014)... New York, N.Y. (PRWEB) September 23, 2014 ... supplement to join the Royal Sport LTD family of ... 100 calories and 20g of pure Whey protein without ... , This ‘Ultra Clean’ protein is available on shelves ... Royal Sport LTD website—where the brand is offering a ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 ADOMANI, Inc. ... serving as President and CEO. He is a 13-year veteran ... former President and CEO of A-Z Bus Sales of Colton, ... of their success, growing their top line revenues, profit and ... their gas or diesel to all-electric or plug-in hybrid ...
(Date:9/23/2014)... 2014 Airbus Helicopters Inc. (AHI) is ... as the 2014 Vision Zero Aviation Safety Award ... database, a free flight safety service the company provides ... - Air Medical Specialist for Airbus Helicopters Inc., presented ... check during the Air Medical Transport Conference Annual Community ...
(Date:9/23/2014)... special issue of the European Journal of Cancer ... research presented during the 1st EORTC Cancer Survivorship Summit ... diagnosis, targeted therapeutics, and more personalized multimodal treatments has ... to a large and rapidly increasing number of cancer ... confronted with a broad spectrum of late adverse treatment ...
Breaking Medicine News(10 mins):Health News:New NIH/DOE grant for life science studies at NSLS-II 2Health News:New NIH/DOE grant for life science studies at NSLS-II 3Health News:Sports Nutrition Brand, Royal Sport LTD, Introduces 'Clean,' Gluten Free Protein Supplement, Royal Sport Ultra Clean 100™ 2Health News:ADOMANI Announces Jim Reynolds to Take Over as President and CEO 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 2Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 3Health News:Protean wins Airbus Helicopters Vision Zero Aviation Safety Award 4
... a significantly enhanced quality of life in old age ... less afraid of death than their less religious peers ... professor of sociology at the University of New Hampshire. ... her collaborator, Paul Wink, professor of psychology at Wellesley ...
... for chronic obstructive pulmonary disease (COPD), can be ... new study. The research, presented at CHEST 2006 ... of the American College of Chest Physicians (ACCP), ... a large proportion of subjects with significant impairment. ...
... years will soon be assessed by a new random-dot stereotest ... article published in the November 2006 // issue of Investigative ... children, 38 with various visual impairments and 18 with normal ... alone with their heads stabilized by a chin and front ...
... law which makes possession of child pornography material a federal ... is a pedophile or become one based on the child ... number of cases are going to court and attorneys are ... person has child porn on their computer," said Dr. Humberto ...
... diabetes in middle age could face more complications later in ... new study.// ,Elizabeth Selvin of the Johns Hopkins Bloomberg ... than 2,800 people aged 65 and above with diabetes who ... the online edition of health Magazine WebMD. ,The ...
... Researchers from the Autonomous University of Tamaulipas are putting teeth ... of pacifiers by babies in their first year of birth, ... alignment in complete disarray. ,Researchers are armed to ... children between the ages of 4 and 5 who were ...
Cached Medicine News:Health News:Religious Adults Have a Higher Quality of Life than Their Peers 2Health News:Large Community Spirometry Screening Proves Successful 2Health News:Does Child pornography lead to Child abuse? 2Health News:Does Child pornography lead to Child abuse? 3
... automated semen analysis, with accurate, consistent, reliable ... Automation provides standardization and ease of use ... analysis. SPERMALITE is a new-generation automated semen ... analysis, and a hard -copy analysis report ...
Stainless Steel. Sterile. 2 pieces/box...
... Cannulated Screw System is part ... systems developed by DePuy ACE ... 3.5mm to 8.0mm. Complete with ... system was designed with the ...
... The first FDA-cleared third-generation allergy test , ... blood testing. It provides quantitative determination of ... excellent precision, accuracy and lot-to-lot reproducibility. The ... hour to help you identify, monitor and ...
Medicine Products: